Pfenex (PFNX) Tops Q4 EPS by 13c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/15/2026
- Wall St wobbles as rising oil and Treasury yields stoke investor unease
- Oil jumps more than $3 as Saudi loadings halt, Libya outages stoke supply fears
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Global AI stocks fall as industry chiefs call for slowing development
- Stocks tend to rise after the Fed starts to hike
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Explainer-How China is preparing for the risk of AI escaping human control
- Global AI stocks fall as industry chiefs call for slowing development
- Citi sees memory market undersupply worsening through 2031
- Enova drops bid to acquire Grasshopper Bancorp, reaffirms guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
March 11, 2019 4:05 PM EDTWe believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors
Several significant milestones across the Companys pipeline are expected in 2019
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfnex Expression Technology platform, the Company has created an advanced pipeline... More
